October was a big month for stem cells. Two approved iPS cell products reached patients in Japan. A diabetes trial showed most people living without insulin shots a year after one infusion. And lab teams found new ways to make better stem cells.
Here are seven stories that stood out, explained in plain words. Each one says what was found, who did it, why it matters, and what we still do not know.
1. Japan treats its first patient with an approved iPS cell therapy for Parkinson’s
What happened: A woman in her 50s got the first transplant of Amchepry, an approved iPS cell product for Parkinson’s disease. The surgery was done at Kyoto University Hospital in October. Japanese news reports say she has left the hospital, gone back to work, and is doing well.
Who: Sumitomo Pharma, the company that makes the product, shared the news in its earnings report on October 30.
How it works: Parkinson’s slowly wipes out the brain cells that make dopamine, a chemical messenger that helps the body move smoothly. iPS cells are adult cells that scientists rewind to a young state, so they can grow into almost any cell. Here, donor iPS cells are grown into early dopamine cells and placed in the brain. Think of it like putting fresh bulbs back into a room that is slowly going dark.
Why it matters: This is the first time the treatment was given as an approved product, not only inside a research trial. In the earlier trial, seven patients got the cells. No major safety problems showed up over two years, and four of them improved.
Caveats: Japan’s approval is conditional and time limited. The company still has to prove safety and benefit in more people. It plans about 20 to 30 transplants by March 2029. One patient doing well early on does not prove it will work for everyone.
Source: AFP report via IOL and Kansai TV report (Japanese)
2. Ten of 12 people with type 1 diabetes stopped needing insulin after one infusion
What was found: Twelve adults with type 1 diabetes got a single infusion of zimislecel, insulin making islet cells grown from stem cells. After one year, all 12 had an HbA1c (a three month blood sugar average) under 7%. Ten of them, or 83%, no longer needed insulin shots at all. Nobody had a severe low blood sugar episode. Time spent in a healthy sugar range rose from about 50% of the day to about 93%.
People also felt better. Their fear of low blood sugar fell by about 65%, and their day to day diabetes stress dropped too.
Who: The therapy is made by Vertex Pharmaceuticals. Dr. Michael Rickels of the University of Pennsylvania presented the results at the Breakthrough T1D Clinical and Research Congress in Philadelphia, as reported by Healio on October 28.
Why it matters: Islet cells work like the body’s sugar thermostat. In type 1 diabetes, the immune system breaks that thermostat. These lab grown cells put a working one back in.
Caveats: The group was small. Everyone had to take drugs that calm the immune system to protect the new cells, and those drugs have side effects. Two people died during the trial, and both deaths were judged not related to the cells. These results come from a conference talk.
Source: Healio report
3. First RiHeart patient recovers well after an iPS heart muscle patch
What happened: A woman in her 50s with severe heart failure was the first person to get RiHeart, a thin sheet of heart muscle cells grown from iPS cells. Her surgery was on September 29 at Osaka Keisatsu Hospital. On October 21, her doctors said she was recovering well and would go home the next day.
Who: The surgery team is led by hospital president Dr. Yoshiki Sawa, who has worked on heart cell sheets for many years. The product is made by Cuorips.
How it works: Think of the sheet as a living bandage placed on a tired heart. It helps the heart grow new blood vessels and work better.
Why it matters: Japan gave RiHeart conditional approval in March. This is the first time it was used as an approved treatment, which moves iPS cell heart repair from the lab toward everyday care.
Caveats: This is one patient, and it is early. Doctors will need to follow more patients for longer to know how well it works.
Source: Kyodo News report
4. One stem cell drip cut broken bones by 94% in women with severe osteoporosis
What was found: Ten women with advanced osteoporosis got one drip of their own bone marrow stem cells. In the two years after, they had 94% fewer broken bones than in the two years before. Their bone mass and bone density went up, and there were no serious side effects.
Who: Dr. Jose M. Moraleda and his team at the Instituto Murciano de Investigación Biosanitaria in Murcia, Spain, working with Dr. Robert Sackstein. The study was published in the journal Cell.
How it works: Stem cells from the bone marrow can help build bone, but when put into a vein, most of them get lost on the way. The team added a sugar tag to the outside of the cells. It works like an address label that helps the cells find their way to bone.
Why it matters: Osteoporosis makes bones weak and easy to break. A single treatment that helps rebuild bone would be a big change. The study also suggests that stem cells from older people can still do repair work.
Caveats: Only 10 women were treated, and there was no comparison group. Each woman was compared with her own past. Bigger, controlled trials are needed to know if it truly works.
Source: Medical Dialogues report and Study in Cell
5. Japan moves to give Stemirac full approval for spinal cord injury
What happened: On October 15, an expert panel of Japan’s health ministry backed full approval for Stemirac, a treatment for spinal cord injury made from a patient’s own bone marrow stem cells. Health Minister Kenichiro Ueno called it groundbreaking. He said some patients who could not walk after their injury were able to walk again with the treatment and rehab.
Who: Stemirac is made by Nipro and was developed with Sapporo Medical University. It first got conditional approval in December 2018.
How it works: Doctors take bone marrow from the patient within about a month of the injury. A lab grows the stem cells into large numbers, and then they go back into the patient through a vein. Think of it as sending a repair crew through the bloodstream to the hurt spinal cord.
Why it matters: It would be the first regenerative medicine product in Japan to move from conditional approval to full approval. That shows the fast track system can work. Two earlier products on that path did not make it.
Caveats: The final approval step was still pending when this was reported. The panel met in private, and the outcome numbers behind the decision have not been made public yet.
Source: Pharma Japan report and BioWorld report
6. A new recipe for iPS cells swaps out a key ingredient
What was found: Making iPS cells usually takes four helper genes, and one of them, OCT4, was thought to be a must. Scientists found that an enzyme called PUS7 can take its place. Cells made with the new mix looked more like true embryonic stem cells. They kept key gene settings in better order, showed less DNA damage, and were better at turning into nerve and blood starter cells.
How it works: PUS7 adds a tiny chemical mark to an RNA called 7SK. That mark helps 7SK team up with a protein group that opens up tightly packed DNA. It is like a key that unlocks a stuffed closet so the right genes can be reached.
Who: Dr. Yanhong Shi’s lab at City of Hope and Dr. Chuan He’s lab at the University of Chicago, with Dr. Hongxia Cai as a lead author. The study was published in Nature Chemical Biology on October 12.
Why it matters: Better quality iPS cells could mean safer and more reliable cell therapies and disease models.
Caveats: This work was done in lab dishes and in mice. The new cells have not been used in any treatment yet, and more checks across the whole genome are still needed.
Source: Study in Nature Chemical Biology
7. From one kind of stem cell, mouse embryo models with blood and a beating heart
What was found: Scientists started with just one type of cell: mouse stem cells pushed into an early, very flexible state using only chemicals. These cells organized themselves into ball shaped structures much like an early embryo. Grown outside the womb, they went on to form embryo models that matched real mouse embryos at about day 8.5, with blood cells and early organs. With more time, they formed beating heart tissue like a day 10.5 embryo.
Who: A team at Tsinghua University in Beijing led by Dr. Tianhua Ma and Dr. Sheng Ding, with Dr. Hua Wu as first author. The study was published in Nature on October 14.
How it works: Think of one seed that grows the whole plant, roots and all. These cells built both the embryo and the support tissues around it on their own.
Why it matters: Models like this help scientists study how blood, the heart, and other organs first form, without needing as many real embryos.
Caveats: This was done in mice, in a dish. These are research models, not real embryos, and they were not placed in a mother.
Source: Study in Nature
That is October. Most of these stories are still early steps. Lab and animal results often change when tested in people, and small trials need bigger ones to confirm them. We will keep tracking what comes next.
This article is for education only. It is not medical or investment advice.